{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:41:53Z","timestamp":1768891313693,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tilvestamab is a highly selective humanised immunoglobulin G1 anti-AXL monoclonal antibody. This phase 1 study evaluated its optimal dose, safety, tolerability, immunogenicity and pharmacokinetics (PK) in relapsed platinum-resistant HGSOC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients received tilvestamab in three dose levels (1\u2009mg\/kg, 3\u2009mg\/kg and 5\u2009mg\/kg) via IV infusion every 2 weeks. Primary objectives included safety, tolerability and PK. Exploratory objectives included overall response, progression-free survival (PFS) and quality-of-life measures. Pharmacodynamic included AXL expression, gene and protein changes by transcriptomic and proteomic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between 25 February 2021 and 4 February 2022, 16 patients were enroled across 8 sites in Singapore, Korea, United Kingdom, and Norway. Median treatment duration was 6.1 weeks. Grade 3 or higher treatment-emergent adverse events occurred in 62.5% patients, but none were tilvestamab-related. Common events included fatigue (38%), anorexia (38%) infections (31%), anaemia (25%) and dyspnoea (25%). No objective responses were observed, but 7 (44%) had stable disease at 6 weeks. PK showed dose-proportional exposure and steady-state by the second dose. Pharmacodynamic analyses revealed reduced fibrosis-related gene signatures and AXL protein expression. Epithelial-mesenchymal transition reversal was seen in 2 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tilvestamab was well-tolerated and further studies to examine the efficacy of AXL inhibition in other indications are required.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>This trial is registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov<\/jats:ext-link>. Registration number: NCT04893551. EudraCT Number: 2020-001382-36<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-03090-6","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:00:29Z","timestamp":1753192829000},"page":"896-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5806-8440","authenticated-orcid":false,"given":"Kenneth","family":"Sooi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-1593","authenticated-orcid":false,"given":"Tuan Zea","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung-Gie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-2591","authenticated-orcid":false,"given":"David","family":"Micklem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-544X","authenticated-orcid":false,"given":"Akil","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-1326","authenticated-orcid":false,"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-3491","authenticated-orcid":false,"given":"Sarah P.","family":"Blagden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-2770","authenticated-orcid":false,"given":"Line","family":"Bjorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David Shao Peng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"3090_CR1","doi-asserted-by":"publisher","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer 2021;149. https:\/\/doi.org\/10.1002\/ijc.33588.","DOI":"10.1002\/ijc.33588"},{"key":"3090_CR2","doi-asserted-by":"publisher","unstructured":"Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 2019;20. https:\/\/doi.org\/10.3390\/ijms20040952.","DOI":"10.3390\/ijms20040952"},{"key":"3090_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2.","journal-title":"Lancet"},{"key":"3090_CR4","doi-asserted-by":"publisher","unstructured":"Bukowski RM, Ozols RF, Markman M. The Management of Recurrent Ovarian Cancer. Semin Oncol 2007;34. https:\/\/doi.org\/10.1053\/j.seminoncol.2007.03.012.","DOI":"10.1053\/j.seminoncol.2007.03.012"},{"key":"3090_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","volume":"140","author":"D Luvero","year":"2019","unstructured":"Luvero D, Plotti F, Aloisia A, Montera R, Terranova C, Carlo De Cicco Nardone. et al. Ovarian cancer relapse: From the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28\u201338. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.014.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3090_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672\u2013705. https:\/\/doi.org\/10.1093\/annonc\/mdz062.","journal-title":"Ann Oncol"},{"key":"3090_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jclinpath-2016-203629","volume":"69","author":"M Brown","year":"2016","unstructured":"Brown M, Black JRM, Sharma R, Stebbing J, Pinato DJ. Gene of the month: Axl. J Clin Pathol. 2016;69:391\u20137. https:\/\/doi.org\/10.1136\/jclinpath-2016-203629.","journal-title":"J Clin Pathol"},{"key":"3090_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1126\/science1061663","volume":"293","author":"Q Lu","year":"2001","unstructured":"Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306\u201311. https:\/\/doi.org\/10.1126\/science1061663.","journal-title":"Science"},{"key":"3090_CR9","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1161\/01.RES.0000223322.16149.9a","volume":"98","author":"VA Korshunov","year":"2006","unstructured":"Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res. 2006;98:1446\u201352. https:\/\/doi.org\/10.1161\/01.RES.0000223322.16149.9a.","journal-title":"Circ Res"},{"key":"3090_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1593\/neo.05640","volume":"7","author":"YS Shieh","year":"2005","unstructured":"Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7:1058\u201364. https:\/\/doi.org\/10.1593\/neo.05640.","journal-title":"Neoplasia"},{"key":"3090_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.0909333107","volume":"107","author":"C Gjerdrum","year":"2010","unstructured":"Gjerdrum C, Tiron C, H\u00f8iby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107:1124\u20139. https:\/\/doi.org\/10.1073\/pnas.0909333107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3090_CR12","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-08-2514","volume":"15","author":"A Gustafsson","year":"2009","unstructured":"Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009;15:4742\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2514.","journal-title":"Clin Cancer Res"},{"key":"3090_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bjc.2013.9","volume":"108","author":"DJ Pinato","year":"2013","unstructured":"Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL, et al. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer. 2013;108:621\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.9.","journal-title":"Br J Cancer"},{"key":"3090_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14:769\u201385. https:\/\/doi.org\/10.1038\/nrc3847.","journal-title":"Nat Rev Cancer"},{"key":"3090_CR15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers12071850","volume":"12","author":"M Tanaka","year":"2020","unstructured":"Tanaka M, Siemann DW. Gas6\/Axl signaling pathway in the tumor immune microenvironment. Cancers. 2020;12:1850 https:\/\/doi.org\/10.3390\/cancers12071850.","journal-title":"Cancers"},{"key":"3090_CR16","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.3390\/ijms20205070","volume":"20","author":"M Bellan","year":"2019","unstructured":"Bellan M, Cittone MG, Tonello S, Rigamonti C, Castello LM, Gavelli F, et al. Gas6\/TAM system: A key modulator of the interplay between inflammation and fibrosis. Int J Mol Sci. 2019;20:5070 https:\/\/doi.org\/10.3390\/ijms20205070.","journal-title":"Int J Mol Sci"},{"key":"3090_CR17","doi-asserted-by":"publisher","first-page":"1400553","DOI":"10.3389\/fimmu.2024.1400553","volume":"15","author":"SM Gr\u00f8ndal","year":"2024","unstructured":"Gr\u00f8ndal SM, Tutusaus A, Boix L, Reig M, Bl\u00f8 M, Hodneland L, et al. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Front Immunol. 2024;15:1400553 https:\/\/doi.org\/10.3389\/fimmu.2024.1400553.","journal-title":"Front Immunol"},{"key":"3090_CR18","doi-asserted-by":"publisher","first-page":"1446672","DOI":"10.3389\/fimmu.2024.1446672","volume":"15","author":"SM Gr\u00f8ndal","year":"2024","unstructured":"Gr\u00f8ndal SM, Bl\u00f8 M, Nilsson LIH, Rayford AJ, Jackson A, Gausdal G, et al. Targeting AXL cellular networks in kidney fibrosis. Front Immunol. 2024;15:1446672 https:\/\/doi.org\/10.3389\/fimmu.2024.1446672.","journal-title":"Front Immunol"},{"key":"3090_CR19","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1164\/rccm.201707-1519OC","volume":"197","author":"MS Espindola","year":"2018","unstructured":"Espindola MS, Habiel DM, Narayanan R, Jones I, Coelho AL, Murray LA, et al. Targeting of TAM receptors ameliorates fibrotic mechanisms in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;197:1443\u201356. https:\/\/doi.org\/10.1164\/rccm.201707-1519OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"3090_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jcmgh.2019.10.010","volume":"9","author":"A Tutusaus","year":"2020","unstructured":"Tutusaus A, de Gregorio E, Cucarull B, Crist\u00f3bal H, Arest\u00e9 C, Graupera I, et al. A Functional Role of GAS6\/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. CMGH. 2020;9:349\u201368. https:\/\/doi.org\/10.1016\/j.jcmgh.2019.10.010.","journal-title":"CMGH"},{"key":"3090_CR21","doi-asserted-by":"publisher","first-page":"e14091","DOI":"10.14814\/phy2.14091","volume":"7","author":"L Landolt","year":"2019","unstructured":"Landolt L, Furriol J, Babickova J, Ahmed L, Eikrem \u00d8, Skogstrand T, et al. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. Physiol Rep. 2019;7:e14091 https:\/\/doi.org\/10.14814\/phy2.14091.","journal-title":"Physiol Rep"},{"key":"3090_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1535-7163.MCT-18-0537","volume":"18","author":"JM Quinn","year":"2019","unstructured":"Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, et al. Therapeutic inhibition of the receptor tyrosine kinase AXL improves sensitivity to platinum and taxane in ovarian cancer. Mol Cancer Ther. 2019;18:389\u201398. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0537.","journal-title":"Mol Cancer Ther"},{"key":"3090_CR23","doi-asserted-by":"publisher","first-page":"ra97","DOI":"10.1126\/scisignal.aaf8175","volume":"9","author":"J Antony","year":"2016","unstructured":"Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal. 2016;9:ra97 https:\/\/doi.org\/10.1126\/scisignal.aaf8175.","journal-title":"Sci Signal"},{"key":"3090_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41416-018-0373-6","volume":"120","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, et al. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer. 2019;120:512\u201321. https:\/\/doi.org\/10.1038\/s41416-018-0373-6.","journal-title":"Br J Cancer"},{"key":"3090_CR25","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1158\/0008-5472.CAN-10-1267","volume":"70","author":"EB Rankin","year":"2010","unstructured":"Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 2010;70:7570\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1267.","journal-title":"Cancer Res"},{"key":"3090_CR26","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0196.","journal-title":"Clin Cancer Res"},{"key":"3090_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166.Integrated","volume":"474","author":"T Cancer","year":"2011","unstructured":"Cancer T, Atlas G. Integrated genomic analyses of ovarian carcinoma the Cancer Genome Atlas Research Network. Nature. 2011;474:609\u201315. https:\/\/doi.org\/10.1038\/nature10166.Integrated.","journal-title":"Nature"},{"key":"3090_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/emmm.201201823","volume":"5","author":"TZ Tan","year":"2013","unstructured":"Tan TZ, Miow QH, Huang RYJ, Wong MK, Ye J, Lau JA, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 2013;5:1051\u201366. https:\/\/doi.org\/10.1002\/emmm.201201823.","journal-title":"EMBO Mol Med"},{"key":"3090_CR29","doi-asserted-by":"publisher","first-page":"107291","DOI":"10.1016\/j.lungcan.2023.107291","volume":"182","author":"S Bhalla","year":"2023","unstructured":"Bhalla S, Fattah FJ, Ahn C, Williams J, Macchiaroli A, Padro J, et al. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2023;182:107291 https:\/\/doi.org\/10.1016\/j.lungcan.2023.107291.","journal-title":"Lung Cancer"},{"key":"3090_CR30","doi-asserted-by":"publisher","unstructured":"Krebs MG, Helland \u00c5, Carcereny Costa E, Arriola Aperribay E, D\u00f3mine G\u00f3mez M, Trigo P\u00e9rez J, et al. OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC. J Thoracic Oncol 2021;16. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.275.","DOI":"10.1016\/j.jtho.2021.01.275"},{"key":"3090_CR31","doi-asserted-by":"publisher","unstructured":"Krebs MG, Branson A, Barber S, Poile C, King A, Greystoke A, et al. Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. Journal of Clinical Oncology 2023;41. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.8511.","DOI":"10.1200\/jco.2023.41.16_suppl.8511"},{"key":"3090_CR32","doi-asserted-by":"publisher","unstructured":"Loges S, Heuser M, Chromik J, Sutamtewagul G, Kapp-Schwoerer S, Crugnola M, et al. Phase Ib\/II Study (NCT02488408 \/ BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results. Blood 2023;142. https:\/\/doi.org\/10.1182\/blood-2023-181833.","DOI":"10.1182\/blood-2023-181833"},{"key":"3090_CR33","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.27492","volume":"61","author":"P Reichl","year":"2015","unstructured":"Reichl P, Dengler M, van Zijl F, Huber H, F\u00fchrlinger G, Reichel C, et al. Axl activates autocrine transforming growth factor-\u03b2 signaling in hepatocellular carcinoma. Hepatology. 2015;61:930\u201341. https:\/\/doi.org\/10.1002\/hep.27492.","journal-title":"Hepatology"},{"key":"3090_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2015.04.013","volume":"63","author":"C B\u00e1rcena","year":"2015","unstructured":"B\u00e1rcena C, Stefanovic M, Tutusaus A, Joannas L, Men\u00e9ndez A, Garc\u00eda-Ruiz C, et al. Gas6\/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol. 2015;63:670\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.013.","journal-title":"J Hepatol"},{"key":"3090_CR35","first-page":"3460","volume":"8","author":"HY Zhu","year":"2016","unstructured":"Zhu HY, Bai WD, Li J, Tao K, Wang HT, Yang XK, et al. Peroxisome proliferator-activated receptor-\u03b3 agonist troglitazone suppresses transforming growth factor-\u03b21 signalling through miR-92b upregulation-inhibited axl expression in human keloid fibroblasts in vitro. Am J Transl Res. 2016;8:3460\u201370.","journal-title":"Am J Transl Res"},{"key":"3090_CR36","doi-asserted-by":"publisher","unstructured":"Bl\u00f8 M, Nilsson LH, Jackson A, Boniecka A, Toombs JE, Ahmed L, et al. Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody. Eur J Cancer 2020;138. https:\/\/doi.org\/10.1016\/s0959-8049(20)31192-8.","DOI":"10.1016\/s0959-8049(20)31192-8"},{"key":"3090_CR37","unstructured":"A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BGB149 Following Single Dose Administration in Healthy Subjects (NCT03795142, unpublished results)."},{"key":"3090_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"3090_CR39","unstructured":"Anderson MD Functional Proteomics RPPA Core n.d. https:\/\/www.mdanderson.org\/research\/research-resources\/core-facilities\/functional-proteomics-rppa-core.html (accessed October 27, 2024)."},{"key":"3090_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.15252\/emmm.201404208","volume":"6","author":"TZ Tan","year":"2014","unstructured":"Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, et al. Epithelial\u2010mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014;6:1279\u201393. https:\/\/doi.org\/10.15252\/emmm.201404208.","journal-title":"EMBO Mol Med"},{"key":"3090_CR41","doi-asserted-by":"publisher","first-page":"14945","DOI":"10.3390\/ijms232314945","volume":"23","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Liu F. Coordination of the AMPK, Akt, mTOR, and p53 Pathways under Glucose Starvation. Int J Mol Sci. 2022;23:14945 https:\/\/doi.org\/10.3390\/ijms232314945.","journal-title":"Int J Mol Sci"},{"key":"3090_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","volume":"25","author":"S Bhalla","year":"2023","unstructured":"Bhalla S, Gerber DE. AXL inhibitors: status of clinical development. Curr Oncol Rep. 2023;25:521\u20139. https:\/\/doi.org\/10.1007\/s11912-023-01392-7.","journal-title":"Curr Oncol Rep"},{"key":"3090_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/path.5191","volume":"247","author":"TZ Tan","year":"2019","unstructured":"Tan TZ, Heong V, Ye J, Lim D, Low J, Choolani M, et al. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer. J Pathol. 2019;247:305\u201319. https:\/\/doi.org\/10.1002\/path.5191.","journal-title":"J Pathol"},{"key":"3090_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","volume":"21","author":"RW Griffiths","year":"2011","unstructured":"Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 2011;21:58\u201365. https:\/\/doi.org\/10.1097\/IGC.0b013e3182049273.","journal-title":"Int J Gynecol Cancer"},{"key":"3090_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: Guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121\u201335. https:\/\/doi.org\/10.1038\/nrm.2017.95.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3090_CR46","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3389\/fphar.2018.00714","volume":"9","author":"F Marcucci","year":"2018","unstructured":"Marcucci F, Rumio C. How tumor cells choose between epithelial-mesenchymal transition and autophagy to resist stress-therapeutic implications. Front Pharm. 2018;9:714 https:\/\/doi.org\/10.3389\/fphar.2018.00714.","journal-title":"Front Pharm"},{"key":"3090_CR47","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10555-024-10169-8","volume":"43","author":"H Fujimoto","year":"2024","unstructured":"Fujimoto H, Yoshihara M, Rodgers R, Iyoshi S, Mogi K, Miyamoto E. et al. Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination. Cancer Metast Rev. 2024;43:1037\u201353. https:\/\/doi.org\/10.1007\/s10555-024-10169-8.","journal-title":"Cancer Metast Rev"},{"key":"3090_CR48","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","volume":"40","author":"D Huang","year":"2021","unstructured":"Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P. et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40:6395\u2013405. https:\/\/doi.org\/10.1038\/s41388-021-02055-2.","journal-title":"Oncogene"},{"key":"3090_CR49","unstructured":"BerGenBio ASA. First-in-human phase 1a\/b study of anti-AXL antibody tilvestamab (BGB324) in patients with advanced solid tumors [poster]. ESMO Virtual Congress \u2013 ENA 2020; 2020 Oct. Available from: https:\/\/bgbwebpagefiles.fra1.cdn.digitaloceanspaces.com\/wp-content\/uploads\/2020\/10\/ENA_2020poster_Tilvestamab_BerGenBio.pdf."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03090-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:53:32Z","timestamp":1758275612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03090-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,5]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03090-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DSPT is an employee of the National University Health System Singapore and reports personal fees for advisory board membership from AstraZeneca, Bayer, BioNTech Boehringer Ingelheim, Eisai, Genmab, GSK, MSD, PMV Pharma, and Roche; personal fees as an invited speaker from AstraZeneca, Eisai, GSK, Merck Serono, MSD, Roche, and Takeda; ownership of stocks\/shares of Asian Microbiome Library (AMiLi); institutional research grants from AstraZeneca, Bayer, Karyopharm Therapeutics, and Roche; institutional funding as coordinating PI from AstraZeneca, MSD, Eisai, Roche and Bergen Bio; institutional funding as local PI from Roche, BioNTech, PMV Pharma, GSK, Sutro Pharma, Bayer, Byondis B.V. and Zeria Pharmaceutical Co Ltd; a previous non-renumerated role as Chair of the Asia Pacific Gynaecologic Oncology Trials Group (APGOT); a previous non-renumerated role as the Society President of the Gynaecologic Cancer Group Singapore; non-renumerated membership of the Board of Directors of the GCIG; research funding from the National Medical Research Council (NMRC) Clinician Scientist Award Senior Investigator Grant (CSASI21jun-0003), the Pangestu Family Foundation Gynaecological Cancer Research Fund; and product samples from AstraZeneca, Eisai, and MSD (non-financial interest) for research trials. JYL reports personal fees for advisory board membership from AstraZeneca, MSD, Regeneron, Merck, ImmunoGen, Genmab and Seagen; personal fees as an invited speaker from AstraZeneca, Eisai, MSD, Roche, Takeda; consulting fees from AstraZeneca, CanariaBio, DS, Eisai, Genmab, GII, ImmunoGen, Merck, MSD, Seagen, Sutro, Regeneron; Grants or contracts from Abbvie, Advenchen, Ascendis Pharma, Alkermes, AstraZeneca, Beigene, BergenBio, BMS, CanariaBio, Corcept, Cellid, CKD, Clovis Oncology, Daiichi Sankyo, Eisai, Genmab, Genemedicine, GII, GSK, ImmunoGen, Janssen, Kelun, Merck, Mersana, MSD, Novartis, Onconic Therapeutics, ONO, Regeneron, Roche, Seagen, Sutro, Synthon, TORL-bio, Takeda, Zymeworks. DJP has received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, Eisai, Falk Foundation, Incyte, Boston Scientific, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, Elevar Therapeutics, EISAI, Roche, DaVolterra, Mursla, Starpharma, Boston Scientific, Exact Sciences and Astra Zeneca; research funding (paid to institution) from MSD, GSK and BMS. CG reports fees for grants from AstraZeneca, GSK, Tesaro, Clovis, MSD, BergenBio, Novartis, Aprea, Nucana, Versatem, Roche, Medannexin and Artios; fees for consulting from AstraZeneca, MSD, GSK, Tesaro, Verastem, Abbvie, and Immunogen; fees for payment\/honoraria from AstraZeneca, MSD, GSK, Tesaro, Clovis, Roche, Nucana, Chugai, Takeda, Cor2Ed, Peervoice, Verastem, Abbvie and Immunogen; fees for participation on a Data Safety Monitoring Board\/Advisory Board from AstraZeneca and MSD. SPB reports Institutional research funding to conduct clinical trials from Nucana PLC, UCB, BioNTech, Medannex, Nurix, Theolytics, Regeneron; Consulting fees from Ellipses, Oxford Drug Design, UCB, Simbec Orion and Theolytics, Directorship of RNA Guardian with ownership interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional review board at each participating site and conducted in accordance with the Declaration of Helsinki and in compliance with GCP guidelines. All patients were required to give written informed consent before participation in the study. Singapore - NHG Domain Specific Review Board ref 2020\/01190. South Korea - IND study MFDS no 202001006; Seoul National University Hospital IRB H-2009-148-1160; Yonsei University Health System, Severance Hospital IRB 2020-2446-002 Study approval no. 4-2020-1160; Samsung Medical Center IRB \u2013 SMC 2020-09-081-003. United Kingdom - REC reference number 20\/LO\/1106 IRAS project ID 286152. Norway - NO REK application ID 168726.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}